Davide Capodanno: Independent Investigators Lead the First Head to Head DOAC Comparison
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in NEJM:
“Finally published: the COBRRA trial, the first randomized head-to-head comparison of major DOACs – something the companies would never have done themselves, as a direct confrontation goes beyond their commercial interests.
This was driven by independent investigators.
The results somewhat support the idea of apixaban being the ‘safer’ DOAC.
That said, the list of study limitations is long, and for me, labeling something as ‘safe’ is not enough — after all, even placebo is ‘safe’ when it comes to bleeding.”
Ali Kamiar, Graduate Student Research Assistant Graduate Student, Research Assistant at University of Miami, Miller School of Medicine, reposted Davide Capodanno’s post on LinkedIn.
“Valuable independent evidence comparing major DOACs. Highlights the importance of critically evaluating both safety endpoints and study limitations when translating data into clinical practice.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 6, 2026, 02:59Preventing Hospital Associated Venous Thromboembolism – Thrombosis Canada
-
Oct 6, 2026, 02:42Treatment of Iron Deficiency With and Without Anemia – American Society of Hematology
-
Oct 6, 2026, 02:36Mouna Sassi: When Clinical and Laboratory Perspectives Meet in Thrombosis Care
-
Oct 6, 2026, 02:35Lucia Stefanini: Platelet Dysfunction and Oxidized Phospholipids in MASLD
-
Oct 6, 2026, 02:18Pablo Corral: Association of Lp(a) With Coronary Atherosclerosis and CV Events
-
Oct 5, 2026, 22:55Steve Humphreys: A Big Thank You to BSHT for Providing Me With a Recent Skills Exchange Award
-
Oct 5, 2026, 22:52William McKeown: Great to Be in Istanbul for the Opening of the EHC 2026
-
Oct 5, 2026, 22:48Laura Quintas Lorenzo: A New Approach to Healthcare for von Willebrand Disease at EHC 2026
-
Oct 5, 2026, 22:46Anas Zayad: Pleased to Share Our New Review on Thrombosis in SCD and Beta Thalassemia